A new class of therapies known as "digital therapeutics" may transform the future of medical care. It could reshape treatments for everything from cancer to diabetes to autism. Below, we take a look at its potential and some recent developments.
Digital therapeutics – software-based disease management solutions – present a novel opportunity for patients to manage chronic diseases. They are gaining more interest as new types of treatments enter the market (click here for a list of some of the most innovative players).
And big pharma is interested.
Through investments and partnerships, pharma giants are dipping their toes into this new area of therapeutics. In fact, nearly all big pharma players have been pursuing strategic partnerships with startups in the space.
Digital therapeutics companies themselves are also looking to partner with one another to strengthen their therapeutic area coverage. For instance, France-based digital therapeutics company Voluntis partnered with diabetes management company Livongo Health to create a combined diabetes platform back in February 2017.